Other At-Risk Groups GLP-1 medications are generally not suitable for individuals with severe gastrointestinal disorders like gastroparesis, those with type 1 diabetes (as these drugs are approved only for type 2 diabetes and obesity), and people with a history of suicidal thoughts, active eating disorders, or heavy alcohol use
doi: 10.1017/S0007114508162997
The University of California Health Data Warehouse proved instrumental in enabling this extensive population-level analysis, demonstrating how integrative data science approaches can accelerate hypothesis generation and validation in biomedical research
PlexusDx offers Semaglutide Injection at $189/mo month-to-month, or from $149/mo on the 6-month plan through licensed 503A compounding pharmacies, available across all 50 states without insurance requirements
Research status Both investigational
In contrast, significant weight loss and optimal glycaemic control generally require several weeks to months of consistent treatment
